OrthoPediatrics Corp. (NASDAQ:KIDS) Shares Purchased by Triodos Investment Management BV

Triodos Investment Management BV raised its position in OrthoPediatrics Corp. (NASDAQ:KIDS) by 29.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 93,000 shares of the company’s stock after buying an additional 21,000 shares during the period. Triodos Investment Management BV owned about 0.38% of OrthoPediatrics worth $2,156,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Wellington Management Group LLP increased its position in shares of OrthoPediatrics by 16.2% in the third quarter. Wellington Management Group LLP now owns 883,221 shares of the company’s stock valued at $23,944,000 after buying an additional 122,846 shares in the last quarter. Barclays PLC grew its position in shares of OrthoPediatrics by 319.3% in the third quarter. Barclays PLC now owns 25,298 shares of the company’s stock valued at $686,000 after purchasing an additional 19,264 shares during the period. Geode Capital Management LLC increased its stake in shares of OrthoPediatrics by 2.1% during the third quarter. Geode Capital Management LLC now owns 391,492 shares of the company’s stock worth $10,615,000 after purchasing an additional 7,972 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of OrthoPediatrics by 125.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock worth $94,000 after purchasing an additional 1,929 shares during the last quarter. Finally, Centiva Capital LP purchased a new position in OrthoPediatrics in the 3rd quarter valued at about $319,000. 69.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $42.00 target price on shares of OrthoPediatrics in a research report on Wednesday, March 5th. Truist Financial decreased their target price on shares of OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus dropped their price target on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th.

OrthoPediatrics Trading Up 1.4 %

Shares of OrthoPediatrics stock opened at $24.75 on Friday. The stock has a 50 day moving average of $24.80 and a 200 day moving average of $25.32. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. The firm has a market capitalization of $601.10 million, a price-to-earnings ratio of -20.12 and a beta of 1.22. OrthoPediatrics Corp. has a fifty-two week low of $21.02 and a fifty-two week high of $35.99.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The company had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. During the same quarter in the prior year, the company posted ($0.23) earnings per share. As a group, research analysts predict that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Insiders Place Their Bets

In other OrthoPediatrics news, CEO David R. Bailey sold 6,620 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $164,573.20. Following the sale, the chief executive officer now directly owns 319,155 shares in the company, valued at $7,934,193.30. This represents a 2.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Fred Hite sold 6,443 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $160,172.98. Following the sale, the chief financial officer now directly owns 207,989 shares in the company, valued at $5,170,606.54. This represents a 3.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,732 shares of company stock worth $589,978 over the last ninety days. Corporate insiders own 31.80% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.